Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns.

Multiple Sclerosis (Houndmills, Basingstoke, England)

Adjuvants, Immunologic, Treatment Failure, Retrospective Studies, drug therapy, Multiple Sclerosis, Relapsing-Remitting, Middle Aged, Male, administration & dosage, Interferon-beta, Humans, Follow-Up Studies, Female, Cohort Studies, Adult, Adolescent

Read this article at

ScienceOpenPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      Estimates of the beta-interferon (IFNB) stopping rate in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) vary and have been mainly derived from multicentre studies. This is a retrospective, hospital chart-based study of 394 patients treated by a single neurologist for up to eight years. The aims of the study were to ascertain the frequency and timing of IFNB discontinuation in a well supported cohort, and to investigate whether the clinical disease type at the initiation of IFNB or the reason for discontinuation influenced stopping rates. The median follow-up was 49 months. The overall IFNB stopping rate was 28% over five years; there was a significant difference between the IFNB stopping rates for RRMS (14%) and SPMS (23%) after three years of follow-up (P =0.0003). Patients stopped IFNB due to side effects after a median of 13 months, and due to failure of therapy after a median of 35 months (P =0.0004). Significantly more patients with SPMS than with RRMS stopped IFNB due to treatment failure (P =0.037). IFNB discontinuation occurred earlier in the treatment course when due to side effects. Stopping IFNB therapy was more common in SPMS and was more often due to treatment failure than side effects.

      Related collections

      Author and article information

      Journal
      15732266

      Comments

      Comment on this article